At a glance
ClinicalIndex Comparison RecordPhase 2Active· 42 enrolled
Drug / intervention
Letrozole +1 moredrug
Likely dose
Letrozole 2.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Letrozole and RAD001 (Everolimus) in Patients With Advanced or Recurrent Endometrial Cancer
In Brief
A Phase 2 clinical trial evaluating Letrozole and RAD001 (Everolimus) for Endometrial Cancer. Active but no longer recruiting, targeting 42 participants across 2 sites.
Detailed Summary
The goal of this clinical research study is to learn if the combination of RAD001 (everolimus) and Femara (letrozole) can help to control recurrent or progressive endometrial cancer. The safety of this drug combination will also be studied.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEndometrial Cancer
CountriesUnited States
CollaboratorsNovartis
Timeline
Phase 2Active
2010201120122013201420152016201720182019202020212022202320242025202620272028
First PostedFeb 2010
Enrollment StartApr 2010
Primary CompletionApr 2022
TodayJul 2026
Study CompletionApr 2028
First PostedFeb 12, 2010
Enrollment StartApr 30, 2010
Primary CompletionApr 1, 2022
Study CompletionApr 30, 2028
TodayJul 2, 2026
Enrollment to primary: 11.9 yearsPosted 16.4 years ago
Interventions
Letrozoledrug
2.5 mg daily by mouth every day, at same time as Everolimus.
RAD001 (Everolimus)drug
10 mg by mouth daily